Shams S, Martinez JM, Dawson JRD, et al. The therapeutic landscape of rheumatoid arthritis: current state and future directions. Front Pharmacol. 2021;12: 680043.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Romao VC, Fonseca JE. Etiology and risk factors for rheumatoid arthritis: a state-of-the-art review. Front Med (Lausanne). 2021;8: 689698.

Article  PubMed  Google Scholar 

Santo RCE, Fernandes KZ, Lora PS, Filippin LI, Xavier RM. Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2018;9:816–25.

Article  PubMed  PubMed Central  Google Scholar 

Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD. Obesity in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:450–62.

Article  PubMed  Google Scholar 

Arias de la Rosa I, Escudero-Contreras A, Ruiz-Ponce M, et al. Molecular changes in the adipose tissue induced by rheumatoid arthritis: effects of disease-modifying anti-rheumatic drugs. Front Immunol. 2021;12:744022.

Article  PubMed  PubMed Central  Google Scholar 

Challener GJ, Myasoedova E, Crowson CS, Giblon RE, Atkinson EJ, Davis JM 3rd. Body mass index trend and variability in rheumatoid arthritis. Clin Rheumatol. 2022;41:349–55.

Article  PubMed  Google Scholar 

Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis. 2016;8:86–101.

Article  PubMed  PubMed Central  Google Scholar 

Feng J, Chen Q, Yu F, et al. Body mass index and risk of rheumatoid arthritis: a meta-analysis of observational studies. Medicine (Baltimore). 2016;95: e2859.

Article  PubMed  Google Scholar 

Masuko K. Rheumatoid cachexia revisited: a metabolic co-morbidity in rheumatoid arthritis. Front Nutr. 2014;1:20.

Article  PubMed  PubMed Central  Google Scholar 

Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C. Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2017;69:157–65.

Article  PubMed  Google Scholar 

Vidal C, Barnetche T, Morel J, Combe B, Daien C. Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol. 2015;42:2261–9.

Article  PubMed  Google Scholar 

Levitsky A, Brismar K, Hafstrom I, et al. Obesity is a strong predictor of worse clinical outcomes and treatment responses in early rheumatoid arthritis: results from the SWEFOT trial. RMD Open. 2017;3: e000458.

Article  PubMed  PubMed Central  Google Scholar 

Singh S, Facciorusso A, Singh AG, et al. Obesity and response to anti-tumor necrosis factor-alpha agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS ONE. 2018;13: e0195123.

Article  PubMed  PubMed Central  Google Scholar 

Lutf A, Hammoudeh M. Weight gain and hair loss during anti-TNF therapy. Int J Rheumatol. 2012;2012: 593039.

Article  PubMed  PubMed Central  Google Scholar 

Alcorn N, Tierney A, Wu O, Gilmour H, Madhok R. Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1571.

Article  PubMed  Google Scholar 

Engvall IL, Tengstrand B, Brismar K, Hafstrom I. Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months. Arthritis Res Ther. 2010;12:R197.

Article  PubMed  PubMed Central  Google Scholar 

Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021;80:848–58.

Article  CAS  PubMed  Google Scholar 

Genovese MC, Kalunian K, Gottenberg JE, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322:315–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westhovens R, Rigby WFC, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80:727–38.

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov. NCT03025308: long term extension study to assess the safety and efficacy of filgotinib in adults with rheumatoid arthritis (FINCH 4). https://clinicaltrials.gov/ct2/show/NCT03025308?term=FINCH+4&draw=2&rank=1. Accessed 17 Jan 2023.

Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheum Dis. 2017;76:1009–19.

Article  CAS  PubMed  Google Scholar 

Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheum Dis. 2017;76:998–1008.

Article  CAS  PubMed  Google Scholar 

ClinicalTrials.gov. NCT02065700: long-term follow-up study of GLPG0634 in active rheumatoid arthritis patients (DARWIN3). https://clinicaltrials.gov/ct2/show/NCT02065700?term=DARWIN+3&draw=2&rank=1. Accessed 17 Jan 2023.

Winthrop K, Tanaka Y, Takeuchi T, et al. Integrated safety analysis update for filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 2.2 years. Arthritis Rheumatol. 2021;73(Suppl 9):1698 (abstract).

Google Scholar 

Dikranian AH, Gonzalez-Gay MA, Wellborne F, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022;8: e002103.

Article  PubMed  PubMed Central  Google Scholar 

Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63:359–64.

Article  CAS  PubMed  Google Scholar 

Ottaviani S, Gardette A, Tubach F, et al. Body mass index and response to infliximab in rheumatoid arthritis. Clin Exp Rheumatol. 2015;33:478–83.

PubMed  Google Scholar 

Gremese E, Carletto A, Padovan M, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res (Hoboken). 2013;65:94–100.

Article  CAS  PubMed  Google Scholar 

Pers YM, Godfrin-Valnet M, Lambert J, et al. Response to tocilizumab in rheumatoid arthritis is not influenced by the body mass index of the patient. J Rheumatol. 2015;42:580–4.

Article  CAS  PubMed  Google Scholar 

Novella-Navarro M, Genre F, Hernandez-Breijo B, et al. Obesity and response to biological therapy in rheumatoid arthritis: the role of body mass index and adipose tissue cytokines. Clin Exp Rheumatol. 2022;40:1726–32.

PubMed  Google Scholar 

McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21:183.

Article  PubMed  PubMed Central  Google Scholar 

Lutsey PL, Zakai NA. Epidemiology and prevention of venous thromboembolism. Nat Rev Cardiol. 2023;20:248–62.

Article  PubMed  Google Scholar 

Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–76.

Article  CAS  PubMed  Google Scholar 

Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis. 2006;6:438–46.

Article  PubMed  Google Scholar 

Wolin KY, Carson K, Colditz GA. Obesity and cancer. Oncologist. 2010;15:556–65.

Article  PubMed  PubMed Central  Google Scholar 

Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL surveillance. Ann Rheum Dis. 2023;82:119–29.

Article  CAS  PubMed  Google Scholar 

Butler SO, Btaiche IF, Alaniz C. Relationship between hyperglycemia and infection in critically ill patients. Pharmacotherapy. 2005;25:963–76.

Article  PubMed  Google Scholar 

Gerchman F, Tong J, Utzschneider KM, et al. Body mass index is associated with increased creatinine clearance by a mechanism independent of body fat distribution. J Clin Endocrinol Metab. 2009;94:3781–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baker JF, George M, Baker DG, Toedter G, Von Feldt JM, Leonard MB. Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:2100–7.

Article  PubMed